Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

(2010) Simon Ekman et al.   ACTA ONCOLOGICA

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

(2010) A Gualberto et al.   BRITISH JOURNAL OF CANCER

Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

(2010) A. Gualberto et al.   CLINICAL CANCER RESEARCH

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH

Figitumumab (CP-751,871) for cancer therapy

(2010) Antonio Gualberto   EXPERT OPINION ON BIOLOGICAL THERAPY

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

(2010) Todd W. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

(2010) E. Buck et al.   MOLECULAR CANCER THERAPEUTICS

Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

(2009) Ashok K. Chakraborty et al.   BREAST CANCER RESEARCH AND TREATMENT

Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo

(2009) X. Zeng et al.   CLINICAL CANCER RESEARCH

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non-Small Cell Lung Cancer Cells

(2009) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling

(2009) T. J. Giordano et al.   CLINICAL CANCER RESEARCH

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

(2009) Mark J Mulvihill et al.   Future Medicinal Chemistry

Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma

(2009) Yi Li et al.   HUMAN PATHOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development

(2009) Mark D. Wittman et al.   JOURNAL OF MEDICINAL CHEMISTRY

IGF-1R targeted treatment of sarcoma

(2009) Jeffrey A Toretsky et al.   LANCET ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells

(2009) Yin-He Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women

(2008) M. J. Gunter et al.   CANCER RESEARCH

Aging and Cancer-Related Loss of Insulin-like Growth Factor 2 Imprinting in the Mouse and Human Prostate

(2008) V. X. Fu et al.   CANCER RESEARCH

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

(2008) J. H. Law et al.   CANCER RESEARCH

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

(2008) F. L. Chen et al.   CLINICAL CANCER RESEARCH

Targeting insulin and insulin-like growth factor signalling in oncology

(2008) Michael Pollak   CURRENT OPINION IN PHARMACOLOGY

Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma

(2008) Jing Wu et al.   GENOMICS

Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models

(2008) Nezha Alami et al.   GROWTH HORMONE & IGF RESEARCH

Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women

(2008) M. J. Gunter et al.   JNCI-Journal of the National Cancer Institute

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

(2008) P. Haluska et al.   MOLECULAR CANCER THERAPEUTICS

Inhaled insulin's last gasp?

(2008) Jim Kling   NATURE BIOTECHNOLOGY

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

The insulin receptor: a prototype for dimeric, allosteric membrane receptors?

(2008) Pierre De Meyts   TRENDS IN BIOCHEMICAL SCIENCES

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells

(2007) Marianna Zavodovskaya et al.   JOURNAL OF CELLULAR BIOCHEMISTRY